Comparing Aspire Biopharma (NASDAQ:ASBP) & Aptiv (NYSE:APTV)

Aspire Biopharma (NASDAQ:ASBP) and Aptiv (NYSE:APTV) are both consumer discretionary companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, earnings, institutional ownership, analyst recommendations, profitability, dividends and risk.

Valuation and Earnings

This table compares Aspire Biopharma and Aptiv”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aspire Biopharma	$10,000.00	1,169.00	-$24.48 million	($69.62)	-0.12
Aptiv	$20.52 billion	0.44	$165.00 million	$1.06	40.59

Aptiv has higher revenue and earnings than Aspire Biopharma. Aspire Biopharma is trading at a lower price-to-earnings ratio than Aptiv, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

19.2% of Aspire Biopharma shares are held by institutional investors. Comparatively, 94.2% of Aptiv shares are held by institutional investors. 5.8% of Aspire Biopharma shares are held by company insiders. Comparatively, 0.1% of Aptiv shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Profitability

This table compares Aspire Biopharma and Aptiv’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Aspire Biopharma	-11,362.21%	N/A	-177.59%
Aptiv	1.17%	17.10%	7.03%

Analyst Ratings

This is a summary of current recommendations and price targets for Aspire Biopharma and Aptiv, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aspire Biopharma	1	0	0	0	1.00
Aptiv	2	4	17	1	2.71

Aptiv has a consensus target price of $73.60, suggesting a potential upside of 71.06%. Given Aptiv’s stronger consensus rating and higher possible upside, analysts clearly believe Aptiv is more favorable than Aspire Biopharma.

Risk and Volatility

Aspire Biopharma has a beta of 0.17, meaning that its stock price is 83% less volatile than the S&P 500. Comparatively, Aptiv has a beta of 1.45, meaning that its stock price is 45% more volatile than the S&P 500.

Summary

Aptiv beats Aspire Biopharma on 13 of the 15 factors compared between the two stocks.

About Aspire Biopharma

Aspire Biopharma Holdings, Inc., early-stage biopharmaceutical company, engages in developing and marketing of disruptive technology for delivery mechanisms for do no harm drugs in the United States. The company provides Sublingual Aspirin Product, which addresses cardiology emergencies and pain management. It develops formulation for a sublingually administered melatonin sleep-aid product; vitamins D, E, and K; testosterone; and semaglutide, as well as formulations for anti-nausea products, anti-psychotic products, ED drugs, seizure medication, and several other classes of drugs. The company was founded in 2021 and is based in Humacao, Puerto Rico.

About Aptiv

Aptiv PLC engages in design, manufacture, and sale of vehicle components in North America, Europe, Middle East, Africa, the Asia Pacific, South America, and internationally. The company provides electrical, electronic, and safety technology solutions to the automotive and commercial vehicle markets. It operates through two segments, Signal and Power Solutions, and Advanced Safety and User Experience. The Signal and Power Solutions segment designs, manufactures, and assembles vehicle’s electrical architecture, including engineered component products, connectors, wiring assemblies and harnesses, cable management products, electrical centers, and hybrid high voltage and safety distribution systems. Its Advanced Safety and User Experience segment provides critical technologies and services for vehicle safety, security, comfort, and convenience, such as sensing and perception systems, electronic control units, multi-domain controllers, vehicle connectivity systems, application software, autonomous driving technologies, and end-to-end DevOps tools. The company was formerly known as Delphi Automotive PLC and changed its name to Aptiv PLC in December 2017. Aptiv PLC was incorporated in 2011 and is based in Dublin, Ireland.